NASDAQ:CORT - Corcept Therapeutics Stock Price, Price Target & More

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.01. The biotechnology company earned $57.66 million during the quarter, compared to the consensus estimate of $58.18 million. Corcept Therapeutics had a return on equity of 46.78% and a net margin of 75.05%. The company's quarterly revenue was up 108.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. View Corcept Therapeutics' Earnings History.

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Corcept Therapeutics.

5 analysts have issued 12-month price targets for Corcept Therapeutics' shares. Their forecasts range from $20.00 to $32.00. On average, they expect Corcept Therapeutics' stock price to reach $26.40 in the next twelve months. View Analyst Ratings for Corcept Therapeutics.

Some companies that are related to Corcept Therapeutics include Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), FibroGen (FGEN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY) and HUTCHISON CHINA/S (HCM).

Press coverage about CORT stock has been trending somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corcept Therapeutics earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Corcept Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.20%), Federated Investors Inc. PA (11.01%), Dimensional Fund Advisors LP (1.37%), Northern Trust Corp (0.97%), Nexthera Capital LP (0.91%) and Russell Investments Group Ltd. (0.68%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Old Mutual Global Investors UK Ltd., Mckinley Capital Management LLC Delaware, PNC Financial Services Group Inc., Oak Ridge Investments LLC, Smith Asset Management Group LP, ClariVest Asset Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Corcept Therapeutics company stock in the last year include David L Mahoney, G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

CORT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Timpani Capital Management LLC, ETRADE Capital Management LLC, State of Tennessee Treasury Department and Federated Investors Inc. PA. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $16.06.

Corcept Therapeutics has a market capitalization of $1.89 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]